Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6165185 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL6165180 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL28097095 | 0.86 | SLC7A5 (0.44) | SLC7A5TAAR1SLC6A2ALPIPKM | |
| SCHEMBL21319341 | 0.85 | SLC7A5 (0.57) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL18171811 | 0.84 | TDP1 (0.44) | SLC7A5DPP4ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL6164900 | 0.84 | SLC7A5 (0.43) | SLC7A5DPP4ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL6164908 | 0.84 | SLC7A5 (0.43) | SLC7A5DPP4ALPIPKMPTGS1 | |
| SCHEMBL18171813 | 0.84 | TDP1 (0.44) | SLC7A5DPP4ALPIPKMPTGS1 | |
| SCHEMBL30959049 | 0.84 | ALPI (0.63) | SLC7A5TAAR1SLC6A2HDAC8ALPI | |
| SCHEMBL1764633 | 0.84 | ALPI (0.63) | SLC7A5TAAR1SLC6A2HDAC8ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-0361482-A1 | Dimethyl tyrosyl amide sulfides, sulfoxides and sulfones | G.D. Searle & Co. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | SLC7A5 1579/4885TAAR1 4590/4885SLC6A2 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.